Unity Biotechnology is a California-based biotech company that focuses on developing therapies to slow, halt, or reverse age-related diseases. The company's current lead drug candidate, UBX1325, is in Phase II clinical trials for treating age-related eye diseases. It also develops other drugs, including UBX1967 for ophthalmologic diseases, UBX2050 for age-related eye diseases, and UBX2089 for multiple neurology indications.